Virpax Pharmaceuticals, INC

Virpax Pharmaceuticals announces Nasdaq delisting due to non-compliance with equity requirements, along with multiple board and executive resignations.

Virpax Pharmaceuticals is set to be delisted from the Nasdaq due to non-compliance with minimum stockholders' equity requirements, accompanied by the resignation of key board members and the CFO.

Virpax Pharmaceuticals enacted a 1-for-25 reverse stock split of its common stock, effective March 21, 2025.

Virpax Pharmaceuticals appoints Charn Deol as an independent director, filling the vacancy left by Jaydriane Panis' resignation.

Jaydriane Panis resigns from Virpax Pharmaceuticals' Board of Directors and associated committees due to compliance requirements with his employer, effective immediately.

Virpax Pharmaceuticals has announced a $6 million public offering of common stock and pre-funded warrants to fund clinical trials, marketing, and general corporate purposes.

Virpax Pharmaceuticals' Q3 2024 report reveals ongoing losses, a significant decrease in cash, and strategic changes including a new CEO and cost-cutting measures.

Virpax Pharmaceuticals reported a net loss of $6.7 million for the first half of 2024, alongside significant changes in its board and financial structure.

Virpax Pharmaceuticals reported a net loss of $3.2 million for the first quarter of 2024 and faces substantial doubt about its ability to continue as a going concern due to ongoing losses and cash obligations.

Virpax Pharmaceuticals details its financial results for 2024, highlighting ongoing losses, efforts to secure additional funding, and strategic shifts in corporate governance and product development.

Virpax Pharmaceuticals files an amendment to its annual report to include the auditor's report and provides updates on its pipeline and financial status.

Virpax Pharmaceuticals files an amendment to its 2022 annual report to include the independent auditor's report, with no other material changes to the original filing.

Virpax Pharmaceuticals outlines its capital structure, stock details, and regulatory compliance in its annual 10-K filing.

Director Katharyn Field acquired 2,500 stock options in Virpax Pharmaceuticals on July 5, 2024, at an exercise price of $0.578.

Director Gary L. Herman of Virpax Pharmaceuticals acquired stock options on July 5, 2024, according to a Form 4 filing with the SEC.

Director Jatinder Dhaliwal reports acquisition of stock options in Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals is holding a special meeting to seek stockholder approval for a reverse stock split and the election of five directors.

Virpax Pharmaceuticals supplements its proxy statement to announce board changes, including director resignations and appointments, and updates director nominees for the upcoming annual meeting on July 29, 2024.

Virpax Pharmaceuticals is asking stockholders to approve amendments to its 2022 Equity Incentive Plan, including increasing the number of shares available for issuance and the evergreen provision percentage, at its upcoming annual meeting.

Virpax Pharmaceuticals is offering up to 2,415,459 shares of common stock and pre-funded warrants in a best efforts public offering to fund drug development and general corporate purposes.

Virpax Pharmaceuticals is seeking to raise capital through a best efforts offering of common stock and pre-funded warrants.

Virpax Pharmaceuticals aims to raise capital through a public offering of common stock and pre-funded warrants to fund clinical trials and for general corporate purposes.

Virpax Pharmaceuticals is offering up to 16,849,200 shares of common stock and pre-funded warrants to raise capital for clinical trials, working capital, and general corporate purposes.

Virpax Pharmaceuticals is conducting a best-efforts public offering of common stock and pre-funded warrants to raise up to $6 million, as it faces financial difficulties and Nasdaq listing compliance issues.

Virpax Pharmaceuticals is offering up to 6,883,260 shares of common stock and pre-funded warrants in a best efforts offering to raise capital for clinical trials, working capital, and general corporate purposes.